search
Back to results

Comparative Usability Evaluation of Sustained Acoustic Medicine (SAM) Devices and Topical Gel for OA Knee Pain

Primary Purpose

Knee Osteoarthritis

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Sustained Acoustic Device with 2.5% Diclofenac Patch
1% Diclofenac Topical Gel
Sponsored by
ZetrOZ, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Knee Osteoarthritis focused on measuring Non-Steroidal Anti-Inflammatory Drugs, Sustained Acoustic Medication, Low-Intensity Continuous Ultrasound

Eligibility Criteria

35 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Physician-diagnosed mild to moderate knee osteoarthritis (KL Grade 2-3) based on fixed-flexion x-ray radiological findings for osteophytes and joint space narrowing within the past 12 months
  • Fulfill the American College of Rheumatology clinical and radiological diagnostic criteria for knee OA
  • 35-80 years of age
  • Report a frequent pain score between 4-7 (NRS range: 0-10) during the week preceding enrollment
  • Report that knee pain negatively affects quality of life
  • Willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved ultrasound gel provided to the subject at the initiation of the study
  • Deemed appropriate by their physician or by the study site physician to participate
  • Willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device
  • Not initiate use of opioid and/or non-opioid analgesic medications
  • Willing to discontinue any other interventional treatment modalities on the knee during the study period

Exclusion Criteria:

  • Cannot successfully demonstrate the ability to put on and take off the device
  • Display any condition which, in the judgment of the investigator, would make participation in the study unacceptable, including, but not limited to, the subject's ability to understand and follow instructions
  • Have severe OA or have little to no cartilage in the knee
  • Have knee replacement, other surgical intervention, or hyaluronidase injection in the affected knee in the past 6 months
  • Is non-ambulatory (unable to walk)
  • Is pregnant
  • Is a prisoner
  • Has a pacemaker
  • Has a malignancy in the treatment area
  • Has an active infection, open sores, or wounds in the treatment area
  • Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia
  • Has known neuropathy
  • Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage)
  • Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening
  • Modify their medications during the course of the study (medications and doses must remain constant throughout the study)
  • Currently taking steroids
  • Have contraindication to radiograph
  • Have a secondary cause of arthritis (metabolic or inflammatory)

Sites / Locations

  • Orthopaedic Foundation
  • ZetrOZ Systems
  • Cayuga Medical Center - Medical Pain Consultants

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

SAM Ultrasound Device and Diclofenac Patch

SAM2 Ultrasound Device and Diclofenac Patch

Topical Pain-Relief Gel

Arm Description

Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.

Patients receive treatment from the wireless SAM Ultrasonic Diathermy Device for 1 hour at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.

Patients apply topical 1% diclofenac gel three times per day, at least 5 days per week for 8 weeks.

Outcomes

Primary Outcome Measures

Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain From Baseline
Change in the self described pain units on a scale by patient at baseline and post-
Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
WOMAC questionnaire will be utilized (Western Ontario and McMaster Universities Arthritis Index) at baseline and post-treatment to calculate the change in scores. WOMAC was divided into 3 categories: pain, stiffness, function and total score. The pain category consists of five scores from 0 - 4, 0 being no pain 4 is worst pain possible, for a range of 0 - 20 points. The stiffness category consists of two scores from 0 - 4, 0 being no stiffness 10 is worst stiffness possible for a range of 0 - 8 points. The function score consists of 17 scores from 0 - 4, 0 being normal function and 10 is severely limited function, for a range of 0 - 68 points. Total score is the sum of pain, stiffness, and function scores (range of 0 - 96).

Secondary Outcome Measures

Full Information

First Posted
September 9, 2021
Last Updated
June 23, 2023
Sponsor
ZetrOZ, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05050448
Brief Title
Comparative Usability Evaluation of Sustained Acoustic Medicine (SAM) Devices and Topical Gel for OA Knee Pain
Official Title
Comparative Usability Evaluation of Sustained Acoustic Medicine (SAM) Devices and Topical Gel for Knee Pain Related to Osteoarthritis
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
August 1, 2021 (Actual)
Primary Completion Date
December 1, 2022 (Actual)
Study Completion Date
December 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ZetrOZ, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the usability of the ultrasound devices and common pain relief gel. The ability of the three treatment approaches to reduce pain, stiffness, and functionality as measured by NRS scale and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) will be evaluated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Osteoarthritis
Keywords
Non-Steroidal Anti-Inflammatory Drugs, Sustained Acoustic Medication, Low-Intensity Continuous Ultrasound

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SAM Ultrasound Device and Diclofenac Patch
Arm Type
Experimental
Arm Description
Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
Arm Title
SAM2 Ultrasound Device and Diclofenac Patch
Arm Type
Experimental
Arm Description
Patients receive treatment from the wireless SAM Ultrasonic Diathermy Device for 1 hour at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
Arm Title
Topical Pain-Relief Gel
Arm Type
Placebo Comparator
Arm Description
Patients apply topical 1% diclofenac gel three times per day, at least 5 days per week for 8 weeks.
Intervention Type
Device
Intervention Name(s)
Sustained Acoustic Device with 2.5% Diclofenac Patch
Other Intervention Name(s)
ZetrOZ Ultrasound Device, Wearable Ultrasound Device, Long Duration Ultrasound, LITUS Device, Long Duration Low-Intensity Device
Intervention Description
Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
Intervention Type
Drug
Intervention Name(s)
1% Diclofenac Topical Gel
Other Intervention Name(s)
Voltaren
Intervention Description
Topical pain-relief gel
Primary Outcome Measure Information:
Title
Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain From Baseline
Description
Change in the self described pain units on a scale by patient at baseline and post-
Time Frame
Through study completion, average of 8 weeks
Title
Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Description
WOMAC questionnaire will be utilized (Western Ontario and McMaster Universities Arthritis Index) at baseline and post-treatment to calculate the change in scores. WOMAC was divided into 3 categories: pain, stiffness, function and total score. The pain category consists of five scores from 0 - 4, 0 being no pain 4 is worst pain possible, for a range of 0 - 20 points. The stiffness category consists of two scores from 0 - 4, 0 being no stiffness 10 is worst stiffness possible for a range of 0 - 8 points. The function score consists of 17 scores from 0 - 4, 0 being normal function and 10 is severely limited function, for a range of 0 - 68 points. Total score is the sum of pain, stiffness, and function scores (range of 0 - 96).
Time Frame
Through study completion, average of 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Physician-diagnosed mild to moderate knee osteoarthritis (KL Grade 2-3) based on fixed-flexion x-ray radiological findings for osteophytes and joint space narrowing within the past 12 months Fulfill the American College of Rheumatology clinical and radiological diagnostic criteria for knee OA 35-80 years of age Report a frequent pain score between 4-7 (NRS range: 0-10) during the week preceding enrollment Report that knee pain negatively affects quality of life Willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved ultrasound gel provided to the subject at the initiation of the study Deemed appropriate by their physician or by the study site physician to participate Willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device Not initiate use of opioid and/or non-opioid analgesic medications Willing to discontinue any other interventional treatment modalities on the knee during the study period Exclusion Criteria: Cannot successfully demonstrate the ability to put on and take off the device Display any condition which, in the judgment of the investigator, would make participation in the study unacceptable, including, but not limited to, the subject's ability to understand and follow instructions Have severe OA or have little to no cartilage in the knee Have knee replacement, other surgical intervention, or hyaluronidase injection in the affected knee in the past 6 months Is non-ambulatory (unable to walk) Is pregnant Is a prisoner Has a pacemaker Has a malignancy in the treatment area Has an active infection, open sores, or wounds in the treatment area Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia Has known neuropathy Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage) Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening Modify their medications during the course of the study (medications and doses must remain constant throughout the study) Currently taking steroids Have contraindication to radiograph Have a secondary cause of arthritis (metabolic or inflammatory)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
George K Lewis, Ph.D.
Organizational Affiliation
ZetrOZ Systems
Official's Role
Principal Investigator
Facility Information:
Facility Name
Orthopaedic Foundation
City
Stamford
State/Province
Connecticut
ZIP/Postal Code
06905
Country
United States
Facility Name
ZetrOZ Systems
City
Trumbull
State/Province
Connecticut
ZIP/Postal Code
06611
Country
United States
Facility Name
Cayuga Medical Center - Medical Pain Consultants
City
Dryden
State/Province
New York
ZIP/Postal Code
13053
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://www.samrecover.com
Description
Class II Medical Device

Learn more about this trial

Comparative Usability Evaluation of Sustained Acoustic Medicine (SAM) Devices and Topical Gel for OA Knee Pain

We'll reach out to this number within 24 hrs